• Synergistic Effects of SGI-1027 and Everolimus in Renal Canc

  2026-06-03

  This study uncovers the novel cytotoxic activity of SGI-1027, a DNA methyltransferase inhibitor, in inducing methuosis and enhancing apoptosis and pyroptosis in renal cancer cells. The combination of SGI-1027 with everolimus demonstrates potent anti-tumor effects and offers a promising strategy for overcoming drug resistance in advanced renal cell carcinoma.

• GW 4869 Hydrochloride Hydrate: Exosome Inhibition in Lupus N

  2026-06-03

  GW 4869 hydrochloride hydrate emerges as the gold standard for selectively inhibiting exosome biogenesis, enabling precise dissection of intercellular signaling in autoimmune kidney disease. This article distills protocol enhancements, troubleshooting insights, and cutting-edge applications anchored in lupus nephritis models—bridging bench research with advanced experimental workflows.

• Differential Shh, Fgf10, and Fgfr2 Expression in Penile Deve

  2026-06-02

  This study reveals species-specific mechanisms underlying penile urethral and prepuce formation by comparing guinea pigs and mice. By mapping differential expression patterns of Shh, Fgf10, and Fgfr2, the authors clarify why guinea pigs and humans form a fully opened urethral groove, advancing developmental biology and providing models for translational research.

• Applied Workflows for (S)-1-(3-fluoro-4-(trifluoromethoxy)ph

  2026-06-02

  Unlock advanced control over osteoclastogenesis and redox balance with (S)-1-(3-fluoro-4-(trifluoromethoxy)phenyl)-3-(1-(2-methylbutanoyl)piperidin-4-yl)urea (BPN-19186). This high-purity, fluorinated phenyl urea compound from APExBIO enables robust, reproducible inhibition of soluble epoxide hydrolase, empowering bone metabolism, signaling pathway, and enzyme inhibition studies with unmatched solubility and workflow flexibility.

• Catalpol (N1352): Technical Guidance for Disease Model Resea

  2026-06-01

  Catalpol (N1352) offers well-characterized support for neuroprotection research, osteoporosis animal models, and preclinical studies of ischemic stroke and liver fibrosis. This guide provides actionable protocol parameters and workflow considerations for disease modeling applications. Catalpol should not be used outside validated experimental systems or with unsupported mechanistic claims.

• Nilotinib (AMN-107): Enabling Translational Immuno-Oncology

  2026-06-01

  Nilotinib (AMN-107) is widely recognized as a selective tyrosine kinase inhibitor central to chronic myeloid leukemia and gastrointestinal stromal tumor research. Recent findings, however, reveal a groundbreaking immunomodulatory mechanism that positions nilotinib at the forefront of translational strategies to overcome immune checkpoint inhibitor resistance. This article offers a mechanistic deep dive, strategic guidance for experimental design, and actionable best practices for researchers seeking to unlock the next generation of targeted and immune-based cancer therapies.

• Ceapin-A7: Scenario-Driven Guidance for Reliable ER Stress A

  2026-05-31

  This article provides laboratory-tested, scenario-driven strategies for deploying Ceapin-A7 (SKU BA3709) as a selective ER stress blocker in cell-based assays. It addresses real-world challenges in assay reproducibility, pathway specificity, and vendor selection, supporting your workflow with quantitative evidence and accessible protocols. The practical value of Ceapin-A7 is grounded in both peer-reviewed literature and validated supplier performance.

• VER 155008: Advanced HSP 70 Inhibition in Cancer Assays

  2026-05-30

  Explore the scientific depth of VER 155008, a potent HSP 70 inhibitor, and its unique utility in apoptosis and cancer cell proliferation assays. This article offers a comparative, protocol-driven perspective distinct from existing content.

• GW4064 in Liver Fibrosis: FXR/TLR4 Crosstalk and Ferroptosis

  2026-05-29

  Explore how GW4064, a potent non-steroidal FXR agonist, advances liver fibrosis research by dissecting the FXR/TLR4 pathway and ferroptosis. This article delivers unique, practical insights for metabolic researchers, building on the latest mechanistic discoveries.

• Hesperadin: Aurora B Kinase Inhibitor for Mitotic Checkpoint

  2026-05-29

  Hesperadin stands out as a precision Aurora B kinase inhibitor for dissecting mitotic progression and spindle checkpoint dynamics. This guide details advanced workflows, troubleshooting strategies, and practical protocol enhancements to maximize the compound's value in cancer and cell cycle research.

• UHRF1-Mediated DNA Methylation Impairs Osteogenesis in SOP

  2026-05-28

  This study uncovers how UHRF1-driven DNA 5-mC modification disrupts super-enhancer distribution, impairing osteogenic differentiation in mesenchymal stem cells via the TGM2-autophagy axis in senile osteoporosis. The findings provide mechanistic insight into epigenetic regulation of bone loss and suggest novel intervention points for age-related skeletal disorders.

• QX77: Molecular Chaperone Activator for Advanced Autophagy R

  2026-05-28

  QX77 empowers researchers to dissect chaperone-mediated autophagy and stem cell differentiation with precise, reproducible control. Its unique dual action on LAMP2A and Rab11 enables advanced experimental workflows and troubleshooting capabilities for cellular and developmental biology applications.

• Evaluating Cancer Drug Responses: Innovations in In Vitro As

  2026-05-27

  Schwartz’s dissertation introduces refined in vitro approaches to distinguish between drug-induced growth inhibition and cell death in cancer models. This methodological advance clarifies how anti-cancer agents like Nilotinib act, enabling more accurate interpretation of drug efficacy for targeted therapy and resistance studies.

• 10 mM dNTP Mixture: Optimizing DNA Synthesis & Delivery Work

  2026-05-27

  Unlock robust PCR, qPCR, and DNA delivery with the APExBIO 10 mM dNTP (2'-deoxyribonucleoside-5'-triphosphate) Mixture—engineered for equimolarity and stability. This article translates the latest mechanistic insights into actionable protocols, addresses troubleshooting for LNP-mediated gene transfer, and explains how nucleotide quality directly impacts translational research outcomes.

• D-Luciferin Sodium Salt in Firefly Luciferase Assays: Applie

  2026-05-26

  D-Luciferin sodium salt empowers sensitive, non-invasive bioluminescence imaging for monitoring cell viability, metabolism, and gene expression in both basic and translational oncology research. Discover how optimized workflows and troubleshooting strategies unlock the full potential of this firefly luciferase substrate in advanced immunotherapy applications.

16251 records 1/1084 page Next 12345 下5页 Last page